Gilead Sciences, Inc.
Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%
Gilead Sciences Accrued rebates and chargebacks liability by Quarter
Accrued rebates and chargebacks liability (Balance Sheet, $M) ($M)
Gilead Sciences Accrued rebates and chargebacks liability: $4,233M in Q2 2026, up 0.4% from a year earlier.
Where the Q2 2026 figure comes from
Source: Form 10-Q (filed 2026-08-06) ↗
Reported in Form 10-Q / 10-K Accrued Liabilities & Critical Accounting Estimates.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Accrued rebates and chargebacks liability (Balance Sheet, $M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 4,233 | +0.4% | Form 10-Q (filed 2026-08-06) ↗ |
| Q1 2026 | Mar 31, 2026 | 4,118 | -1.6% | Form 10-Q (filed 2026-05-07) ↗ |
| Q4 2025 | Dec 31, 2025 | 4,337 | +11.4% | Form 10-Q (filed 2026-08-06) ↗ |
| Q3 2025 | Sep 30, 2025 | 4,931 | +19.9% | Form 10-Q (filed 2025-11-07) ↗ |
| Q2 2025 | Jun 30, 2025 | 4,215 | +7.4% | Form 10-Q (filed 2025-08-07) ↗ |
| Q1 2025 | Mar 31, 2025 | 4,185 | -1.8% | Form 10-Q (filed 2025-05-07) ↗ |
| Q4 2024 | Dec 31, 2024 | 3,892 | +2.4% | Form 10-K (filed 2026-02-24) ↗ |
| Q3 2024 | Sep 30, 2024 | 4,113 | +10.7% | Form 10-Q (filed 2024-11-12) ↗ |
| Q2 2024 | Jun 30, 2024 | 3,923 | +12.3% | Form 10-Q (filed 2024-08-08) ↗ |
| Q1 2024 | Mar 31, 2024 | 4,263 | +22.6% | Form 10-Q (filed 2024-05-08) ↗ |
| Q4 2023 | Dec 31, 2023 | 3,802 | +9.3% | Form 10-K (filed 2025-02-28) ↗ |
| Q3 2023 | Sep 30, 2023 | 3,714 | – | Form 10-Q (filed 2023-11-07) ↗ |
| Q2 2023 | Jun 30, 2023 | 3,494 | – | Form 10-Q (filed 2023-08-04) ↗ |
| Q1 2023 | Mar 31, 2023 | 3,477 | – | Form 10-Q (filed 2023-05-03) ↗ |
| Q4 2022 | Dec 31, 2022 | 3,479 | +7.2% | Form 10-K (filed 2024-02-23) ↗ |
| Q4 2021 | Dec 31, 2021 | 3,244 | – | Form 10-K (filed 2023-02-22) ↗ |
Breakdown
What makes up accrued rebates and chargebacks liability
- Total gross-to-net (GTN) deductions ($M)–
- Gross-to-net deductions as % of gross product sales (%)–
- Rebates & chargebacks rollforward — Beginning balance ($M)–
- Rebates & chargebacks rollforward — Total provision (decrease to product sales, $M)–
- Rebates & chargebacks rollforward — Total payments ($M)–
- Rebates & chargebacks rollforward — Ending balance ($M)–
Cite this data
StockData. (2026). Gilead Sciences Accrued rebates and chargebacks liability ($M), quarterly Q4 2021–Q2 2026 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/gtn-rebates-liab
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.